Mediator release is altered in immunotherapy-treated patients: A 4-year study

被引:0
|
作者
Dokic, D [1 ]
Nethe, A [1 ]
KleineTebbe, J [1 ]
Kunkel, G [1 ]
Baumgarten, CR [1 ]
机构
[1] FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, DEPT CLIN IMMUNOL & ASTHMA, OPD, D-13353 BERLIN, GERMANY
关键词
immunotherapy; mediator release; specific IgG antibodies;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
In recent years, it has been possible to demonstrate mediator release into the nasal secretion after nasal allergen challenge in patients with allergic rhinitis. Using the nasal provocation model, we determined whether the mediator release was altered in immunotherapy-treated patients. Seventeen grass-pollen-allergic patients were examined under controlled, reproducible conditions. Serial challenges with increasing doses of grass pollen produced increasing numbers of clinical symptoms and release of mediators such as kinins, TAME-esterase activity and histamine. Ten patients received a semidepot perennial grass-pollen extract for 4 years. Seven patients served as controls and did not receive immunotherapy during the observation period. Data from the group of patients receiving immunotherapy over the first year already showed a partially significant decline in the maximal mediator release after nasal allergen challenges compared to the results of pretreated challenges, whereas controls did not show any significant changes. Nasal allergen challenges after termination of 4 years' immunotherapy significantly modified the mediator release compared to pretreatment values (TAME-esterase activity P < 0.05, kinins P < 0.01, and histamine P < 0.01). Decrease of mediator release paralleled the symptom-medication scores and quantitative skin prick test. Finally, we could demonstrate a significant correlation between specific IgG increase and mediator decrease in the treated group.
引用
收藏
页码:796 / 803
页数:8
相关论文
共 44 条
  • [1] Is there an Association between Lymph Node Size and Hyperprogression in Immunotherapy-Treated Patients?
    Alkader, Mohammad S.
    Altaha, Rashed Z.
    Jabali, Eslam H.
    Attieh, Ola A.
    Matalqa, Ala' W.
    ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2024, 62 (01) : 33 - 43
  • [2] The Cross-Scale Association between Pathomics and Radiomics Features in Immunotherapy-Treated NSCLC Patients: A Preliminary Study
    Dia, Abdou Khadir
    Ebrahimpour, Leyla
    Yolchuyeva, Sevinj
    Tonneau, Marion
    Lamaze, Fabien C.
    Orain, Michele
    Coulombe, Francois
    Malo, Julie
    Belkaid, Wiam
    Routy, Bertrand
    Joubert, Philippe
    Despres, Philippe
    Manem, Venkata S. K.
    CANCERS, 2024, 16 (02)
  • [3] Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer
    Oronsky, Bryan
    Larson, Chris
    Reid, Tony R.
    Carter, Corey A.
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2018, 6
  • [4] Regulatory T and B cells in peripheral blood of subcutaneous immunotherapy-treated Japanese cedar pollinosis patients
    Matsuda, Masaya
    Terada, Tetsuya
    Tsujimoto, Nau
    Morie, Yuki
    Ishida, Tomoki
    Takahashi, Hiromu
    Hamaguchi, Junpei
    Tabuchi, Yuki
    Doi, Kana
    Noro, Keiki
    Kikuoka, Yusuke
    Omura, Shuji
    Yoshida, Takuya
    Ayani, Yusuke
    Suzuki, Manabu
    Ichihara, Takahiro
    Inaka, Yuko
    Inui, Takaki
    Kawata, Ryo
    Nabe, Takeshi
    IMMUNOTHERAPY, 2019, 11 (06) : 473 - 482
  • [5] GRASS-POLLEN IMMUNOTHERAPY - EFFICACY AND SAFETY DURING A 4-YEAR FOLLOW-UP-STUDY
    WALKER, SM
    VARNEY, VA
    GAGA, M
    JACOBSON, MR
    DURHAM, SR
    ALLERGY, 1995, 50 (05) : 405 - 413
  • [6] Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
    Mao Y.
    Gide T.N.
    Adegoke N.A.
    Quek C.
    Maher N.
    Potter A.
    Patrick E.
    Saw R.P.M.
    Thompson J.F.
    Spillane A.J.
    Shannon K.F.
    Carlino M.S.
    Lo S.N.
    Menzies A.M.
    da Silva I.P.
    Long G.V.
    Scolyer R.A.
    Wilmott J.S.
    Journal of Translational Medicine, 21 (1)
  • [7] Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
    Clancy, Kate
    Hamill, Chelsea S.
    O'Neill, W. Quinn
    Vu, Brandon
    Thuener, Jason
    Gui, Shanying
    Li, Shawn
    Fowler, Nicole
    Rezaee, Rod
    Lavertu, Pierre
    Wasman, Jay
    Patel, Monaliben
    Shaikh, Hira
    Vick, Eric
    Madabhushi, Anant
    Wise-Draper, Trisha M.
    Burkitt, Kyunghee
    Teknos, Theodoros N.
    Pan, Quintin
    CANCERS, 2021, 13 (19)
  • [8] Improved Survival of Elderly Patients with NSCLC Treated in the Immunotherapy Era: A Historical Cohort Study
    Pelizzari, G.
    Targato, G.
    Corvaja, C.
    Fantin, A.
    De Maglio, G.
    Rossetto, C.
    Rizzato, S.
    Fasola, G.
    Follador, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S998 - S999
  • [9] RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study
    Garcia Martinez, F.
    Fernandez-Velilla Pena, M.
    Cruz Castellanos, P.
    De Castro Carpeno, J.
    Pertejo, A.
    Torres Sanchez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S980 - S980
  • [10] Machine learning models in the prediction of one-year mortality in patients with advanced hepatocellular cancer treated with immunotherapy
    Lui, Thomas Ka Luen
    Cheung, Michael Ka Shing
    Leung, Wai Keung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 59 - 60